Page last updated: 2024-11-11

Isolicoflavonol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID5318585
CHEMBL ID457679
CHEBI ID175544
SCHEMBL ID5614138

Synonyms (30)

Synonym
CHEBI:175544
3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one
isolicoflavonol
MLS000697735 ,
smr000470986
cid_5318585
bdbm50251003
CHEMBL457679 ,
LMPK12111984
HMS2271L11
sr-01000765807
SR-01000765807-2
SCHEMBL5614138
PGCKDCPTJAQQSQ-UHFFFAOYSA-N
94805-83-1
3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-butenyl)phenyl]-4h-1-benzopyran-4-one, 9ci
3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-butenyl)phenyl]-4h-1-benzopyran-4-one
4',5,7-trihydroxy-3'-prenylflavonol
5,7,4'-trihydroxy-3'-prenylflavonol
4h-1-benzopyran-4-one, 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-butenyl)phenyl]- (9ci); 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-4h-1-benzopyran-4-one
MS-25516
4h-1-benzopyran-4-one,3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-butenyl)phenyl]-
DTXSID801317129
CS-0024333
HY-N3474
GLXC-18948
AKOS040760475
3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-4h-1-benzopyran-4-one
4h-1-benzopyran-4-one, 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-
355E7H7EHH
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
flavonesA member of the class of flavonoid with a 2-aryl-1-benzopyran-4-one (2-arylchromen-4-one) skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency19.95260.707912.194339.8107AID720542
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency35.48133.548119.542744.6684AID743266
DNA polymerase eta isoform 1Homo sapiens (human)Potency19.95260.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency56.23410.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.73080.004611.374133.4983AID624296
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency28.18380.07578.474229.0628AID602233
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseHomo sapiens (human)IC50 (µMol)0.10000.00001.290410.0000AID357965
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endoribonuclease toxin MazFEscherichia coli str. K-12 substr. MG1655EC50 (µMol)56.50003.96009.515717.4000AID588481; AID588502
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
protein AF-9 isoform aHomo sapiens (human)AC5017.15000.08008.380217.9800AID720495
glycogen synthase kinase-3 alphaHomo sapiens (human)AC509.40200.013529.7434171.7000AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID357965Inhibition of aromatase from human placental microsomes2001Journal of natural products, Oct, Volume: 64, Issue:10
Aromatase inhibitors from Broussonetia papyrifera.
AID1432493Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 200 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1301467Inhibition of recombinant human PTP1B assessed as hydrolysis of p-nitrophenyl phosphate at 25 uM after 30 mins relative to control2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine.
AID1432491Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 20 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432494Inhibition of Escherichia coli N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 20 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432500Antibacterial activity against Bacillus subtilis NBRC 3134 after overnight incubation by MTT assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432496Inhibition of Escherichia coli N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 200 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432495Inhibition of Escherichia coli N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 100 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432497Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) at 100 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432499Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ V307R mutant GTPase activity expressed in Escherichia coli BL21 (DE3) after 1 hr relative to wild type protein2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432492Inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) assessed as residual activity at 100 uM after 1 hr relative to control2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
AID1432498Uncompetitive inhibition of Bacillus subtilis N-terminal hexahistidine-tagged FtsZ GTPase activity expressed in Escherichia coli BL21 (DE3) after 1 hr by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Filamenting temperature-sensitive mutant Z inhibitors from Glycyrrhiza glabra and their inhibitory mode of action.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]